Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Starry Pharmaceutical Co's Days Payable or its related term are showing as below:
SHSE:603520'
s Days Payable Range Over the Past 10 Years
Min: 55.08 Med: 107.72 Max: 140.83
Current: 82.19
During the past 13 years, Zhejiang Starry Pharmaceutical Co's highest Days Payable was 140.83. The lowest was 55.08. And the median was 107.72.
SHSE:603520's Days Payable is ranked worse than 54.48% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.28
vs SHSE:603520: 82.19
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Starry Pharmaceutical Co Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Starry Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Starry Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Starry Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Zhejiang Starry Pharmaceutical Co's Days Payable falls into.
Zhejiang Starry Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Starry Pharmaceutical Co (SHSE:603520) has a Days Payable of 64.55 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Starry Pharmaceutical Co and its competitors. This is 40% below median its historical median of 107.72. Over the past decade, Zhejiang Starry Pharmaceutical Co's Days Payable has ranged from 55.08 to 140.83. According to the industry distribution chart, Zhejiang Starry Pharmaceutical Co ranks #505 out of 927 companies in the Drug Manufacturers industry, placing it in the top 54.5%.
Is Zhejiang Starry Pharmaceutical Co's Days Payable too high?
Zhejiang Starry Pharmaceutical Co's current Days Payable of 64.55 is 40% below median its 10-year median of 107.72. Over the past 10 years, this metric has ranged from a low of 55.08 to a high of 140.83. The Drug Manufacturers industry median Days Payable is 90.28. Zhejiang Starry Pharmaceutical Co's value of 64.55 is 28.5% below this industry median. Based on the distribution chart, Zhejiang Starry Pharmaceutical Co ranks #505 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zhejiang Starry Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Starry Pharmaceutical Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Starry Pharmaceutical Co ranks #505 out of 927 companies for Days Payable. This places Zhejiang Starry Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.28. Zhejiang Starry Pharmaceutical Co's value of 64.55 is 28.5% below this benchmark. Historically, Zhejiang Starry Pharmaceutical Co's own Days Payable has ranged from 55.08 to 140.83 over the past decade. While the company's 10-year median is 107.72 vs. the industry median of 90.28, Zhejiang Starry Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Starry Pharmaceutical Co's current Days Payable of 64.55 is 28.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang Starry Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Starry Pharmaceutical Co's current Days Payable is 64.55, which is 40% below median its own 10-year median of 107.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Starry Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co (SHSE:603520) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.94, compared to a current price of ¥8.66 — trading 20.8% below its estimated fair value. The current Days Payable is 64.55, which is 40% below median its 10-year median of 107.72 and 28.5% below the Drug Manufacturers industry median of 90.28. Zhejiang Starry Pharmaceutical Co's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zhejiang Starry Pharmaceutical Co (SHSE:603520), the current Days Payable is 64.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Starry Pharmaceutical Co (SHSE:603520) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.66 is trading 20.8% below its estimated GF Value™ of ¥10.94.
GuruFocus considers Zhejiang Starry Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603520:
Days Payable: 64.55 (40% below median its 10-year median of 107.72)
GF Value™: ¥10.94 vs. price of ¥8.66 (20.8% below fair value)
Industry Position: 28.5% below the Drug Manufacturers median (#505 of 927)
No single metric tells the full story. See the SHSE:603520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
77GF Score
Get the complete analysis for SHSE:603520
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603520 has been successfully added to your 
